Effect of Antiresorptive Therapy on Urinary Hydroxyproline in Postmenopausal Osteoporosis

Question of the interrelationship of systemic disorders of bone remodeling and the condition of the bone tissue of the alveolar bone, as well as the efficiency of comprehensive antiresorptive therapy at different stages of surgical rehabilitation in dentition defects in female patients with postmenopausal osteoporosis (PMOP) requires further clarification and remains a subject of active discussion of scientists and clinicians. In the study there was demonstrated that in PMOP female patients with atrophy of the alveolar process of the maxilla in edentulous area there is noted was a significant excess in indices of bone turnover (TNF-alpha level - by 184%, IL-1 - 224%, IL-6- 85%, CTx -156% osteocalcin - 32.9%, PTH- 55%) against the background of the reduced level of a D(OH)25 (by 25.8%) in comparison with patients of reproductive age without osteoporosis. These data correlate with a significant increase in indices of osteosynthesis (index level of the osteoid volume - by 17.6%, index of total resorptive surface by - 51.5%) and a decrease in bone quality indices (index level of the total volume of trabecules - by 60%, index of average width of trabeculae - by 40 %) according to results of the histological examination of bioptate of the process from the edentulous area. At that in PMOP patients with concomitant accompanying somatic pathology the level of TNF-a, IL-1, IL-6 and CTx was significantly higher than in patients of this the group without comorbidity. Appointment of the comprehensive antiresorptive therapy at all stages of surgical rehabilitation (open sinus lifting, dental implantation) in PMOP patients with atrophy of the maxilla in edentulous area during the year before and after sinus lifting significantly increasedthe efficiency of the dental implant. Supplementation of NSAIDs (Arcoxia 60 mg per day) for 2 months prior to dental implantation and within 1 month after a comprehensive antiresorptive therapy in PMOP patients with concomitant estrogen-induced pathology also significantly increases the efficiency of the dental implant in comparison with given indices in patients which received no combined therapy.

Download Full-text

OP0113 Increases in bone mineral density explain the reduction in incidence of nonvertebral fractures seen with antiresorptive therapy in women with postmenopausal osteoporosis

10.1136/annrheumdis-2001.634 ◽

2001 ◽

Author(s):

RD Wasnich ◽

MC Hochberg ◽

S Greenspan ◽

PD Ross ◽

PD Miller

Keyword(s):

Bone Mineral Density ◽

Postmenopausal Osteoporosis ◽

Bone Mineral ◽

Antiresorptive Therapy ◽

Mineral Density ◽

Nonvertebral Fractures

Download Full-text

Antiresorptive Therapy for the Prevention of Postmenopausal Osteoporosis

Treatments in Endocrinology ◽

10.2165/00024677-200504050-00001 ◽

2005 ◽

Vol 4 (5) ◽

pp. 263-277 ◽

Cited By ~ 8

Author(s):

Peter Vestergaard

Keyword(s):

Postmenopausal Osteoporosis ◽

Antiresorptive Therapy

Download Full-text

The influence of individual genetic polymorphisms on postmenopausal osteoporosis treatment effectiveness

Medical Herald of the South of Russia ◽

10.21886/2219-8075-2020-11-4-58-66 ◽

2020 ◽

Vol 11 (4) ◽

pp. 58-66

Author(s):

N. A. Reznichenko ◽

V. V. Simrok ◽

A. G. Adunts

Keyword(s):

Bone Mineral Density ◽

Postmenopausal Osteoporosis ◽

Treatment Effectiveness ◽

Lumbar Vertebrae ◽

Osteoporosis Treatment ◽

Antiresorptive Therapy ◽

Mineral Density ◽

Vdr Gene ◽

Therapy Effectiveness ◽

Left And Right

Objective: study of associations between VDR gene rs1544410 and rs10735810 polymorphisms, MCM6 gene rs4988235, CALCR gene rs1801197 one and ibandronate efficacy in women with postmenopausal osteoporosis.Materials and methods: 117 women with postmenopausal osteoporosis were examined for 12 months in the dynamics of treatment with ibandronate. Evaluation of therapy effectiveness was based on indicators of increase in bone mineral density in L1-L4 lumbar vertebrae, as well as left and right femurs.Results: An association of GG genotype of VDR gene rs1544410 polymorphism with low growth rates of mineral density of L1-L4 lumbar vertebrae (3,41 ± 0,60 % versus 5,51 ± 0,78 % in other women; р = 0,036) was established. The effect of other studied polymorphisms (rs10735810 of VDR gene, rs4988235 of MCM6 gene, rs1801197 of CALCR gene) on treatment effectiveness was not found.Conclusion: it is advisable to use obtained results when developing personalized regimens for antiresorptive therapy for women with postmenopausal osteoporosis.

Download Full-text

Current bone mineral density data on bisphosphonates in postmenopausal osteoporosis

Bone ◽

10.1016/s8756-3282(96)90165-9 ◽

1996 ◽

Vol 19 (5) ◽

pp. S195-S198 ◽

Cited By ~ 15

Author(s):

M MCCLUNG

Keyword(s):

Bone Mineral Density ◽

Postmenopausal Osteoporosis ◽

Bone Mineral ◽

Mineral Density ◽

Density Data

Download Full-text

Rationale, baseline characteristics and methodology of the non-interventional VIVA study in postmenopausal osteoporosis

Osteologie/Osteology ◽

10.1055/s-0037-1620027 ◽

2014 ◽

Vol 23 (01) ◽

pp. 49-55

Author(s):

L. C. Hofbauer ◽

D. Felsenberg ◽

M. Amling ◽

A. Kurth ◽

P. Hadji

Keyword(s):

Quality Of Life ◽

Postmenopausal Osteoporosis ◽

Primary Outcome ◽

Osteoporosis Treatment ◽

Secondary Outcome ◽

Matched Pairs ◽

Fracture History ◽

Baseline Characteristics ◽

Study Inclusion

SummaryIt is important to understand compliance and persistence with medication use in the clinical practice of osteoporosis treatment. The purpose of this work is to describe the “intravenous ibandronate versus oral alendronate” (VIVA) study, a non-interventional trial to assess the compliance and persistence of osteopenic postmenopausal women with treatment via weekly oral alendronate or intravenous ibandronate (Bonviva®) every three months.4477 patients receiving ibandronate 3 mg i. v. quarterly and 1491 patients receiving alendronate 70 mg orally weekly were included in the study. Matched pairs of 901 subjects in each group were also generated. Matching was performed on the basis of age, body mass index, fracture history at study inclusion, prior treatment with bisphosphonates and the number of concomitant disorders. Secondary outcome measures of osteoporosis related fractures, mobility restriction and pain, analgesia, quality of life questionnaires as well as attitudes to medications were assessed. The primary outcome parameters of compliance and persistence will be tracked in these subjects.At baseline, the entire collectives differed significantly on body weight (less in ibandronate group), duration since osteo - porosis diagnosis (longer in ibandronate), and incidence of prior osteoporotic fracture (higher in ibandronate group). The matched-pairs differed only on mobility restriction and quality of life (both worse in ibandronate group).The results from the VIVA study trial will provide scientific rationale for clinical recommendations in the pharmacological treatment of postmenopausal osteoporosis.

Download Full-text